Deadline Date: October 12, 2026
The Quarterly Research Grant Funding Programme supports preclinical and clinical research projects dedicated to slowing, stopping, or reversing Parkinson’s disease through disease-modifying approaches rather than symptomatic treatment.
The programme focuses on disease modification research, preclinical research with a realistic pathway to clinical testing within five years, clinical research involving people with Parkinson’s, translational research, clinical infrastructure projects, and clinical sub-studies that advance the development of therapies targeting the progression of Parkinson’s disease.
The Quarterly Research Grant Funding Programme is an open funding opportunity supporting both preclinical and clinical research aimed at developing treatments that can modify the course of Parkinson’s disease. The programme does not support research that is solely directed at relieving symptoms. Instead, it prioritises projects with strong potential to progress toward clinical application within a realistic timeframe.
Preclinical research proposals must include a clearly identified clinical candidate and present an achievable plan demonstrating how the research could advance to testing in people with Parkinson’s within five years. Clinical research proposals must involve people living with Parkinson’s, as studies conducted exclusively with healthy volunteers are not eligible for funding.
Funding is available internationally to both academic institutions and commercial organisations, either independently or in collaboration. Preclinical research projects can receive funding of up to £300,000, while clinical infrastructure projects and sub-studies are typically supported with grants ranging from £75,000 to £300,000. Funding for clinical trials depends on the stage of the trial. Applicants planning late-stage clinical trials or proposing novel clinical trial designs are encouraged to contact Cure Parkinson’s before submitting an application.
Commercial applicants are required to submit additional information describing their organisation and financial background. Applications may undergo a confidential commercial review to assess the justification of costs, understand the broader commercial context, and evaluate whether successful research outcomes can ultimately benefit people with Parkinson’s.
Eligible host organisations may be academic or commercial entities but must be legally constituted, research active, and capable of carrying out the proposed work. They must demonstrate appropriate research governance, comply with standards for animal and human research where applicable, provide an institutional letter of support, and be able to meet the grant terms and conditions established by Cure Parkinson’s.
For more information, visit Cure Parkinson’s.
